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The paracaspase domain of MALT1 (mucosa-associated lymph-
oid tissue lymphoma translocation protein 1) is a component
of a gene translocation fused to the N-terminal domains of
the cellular inhibitor of apoptosis protein 2. The paracaspase
itself, commonly known as MALT1, participates in the NF-κB
(nuclear factor κB) pathway, probably by driving survival
signals downstream of the B-cell antigen receptor through
MALT1 proteolytic activity. We have developed methods for the
expression and puriﬁcation of recombinant full-length MALT1
and its constituent catalytic domain alone. Both are activated
by dimerization without cleavage, with a similar dimerization
barrier to the distantly related cousins, the apical caspases.
By using positional-scanning peptidyl substrate libraries we
demonstratethattheactivityandspeciﬁcityoffull-lengthMALT1
isrecapitulatedbythecatalyticdomainalone,showingastringent
requirement for cleaving after arginine, and with striking peptide
length constraints for efﬁcient hydrolysis. Rates of cleavage
(kcat/Km values) of optimal peptidyl substrates are in the same
order (10
3–10
4 M
−1 ·s
−1) as for a putative target protein CYLD.
Thus MALT1 has many similarities to caspase 8, even cleaving
the putative target protein CYLD with comparable efﬁciencies,
but with diametrically opposite primary substrate speciﬁcity.
Key words: CYLD, mucosa-associated lymphoid tissue
lymphoma translocation protein 1 (MALT1), paracaspase, pos-
itional-scanning substrate library, protease, substrate speciﬁcity.
INTRODUCTION
The human protein MALT1 (mucosa-associated lymphoid tissue
lymphoma translocation protein 1) was discovered over a
decade ago as a component of a genetic translocation. In this
translocation, the MALT1 gene is fused to the gene encoding
cIAP2 [cellular IAP (inhibitor of apoptosis protein) 2] [1,2].
The protein product of this gene fusion contains the N-terminal
domains of cIAP2 fused to the C-terminal region of MALT1.
Although it was soon realized that MALT1 plays a part in the
NF-κB (nuclear factor κB) pathway [2], the exact nature of its
function remains under investigation.
It has been proposed that antigen receptor engagement leads
to the phosphorylation of the adaptor protein CARMA1 [CARD
(caspase recruitment domain)-containing MAGUK (membrane-
associated guanylate kinase) 1] (also known as CARD11),
followed by recruitment of MALT1 and its constitutive binding
partner Bcl10 [3–6]. CARMA1, Bcl10 and MALT1 together
form the CBM complex, which serves as a binding platform
for several other proteins, among them TRAF6 [TNF (tumour-
necrosis-factor)-receptor-associated factor] and NEMO (NF-κB
essential modulator) also known as IKKγ [IκB (inhibitor of NF-
κB) kinase] [7], which leads to the induction of NF-κBt a r g e t
genes.
Full-length MALT1 is made up of several domains.
Downstream of a DD (death domain) and Ig-like domains,
MALT1 contains a region which shows similarity to the caspase
family of proteases [2] (Figure 1A). After initial unsuccessful
attempts to demonstrate proteolytic activity [8], two groups
independently reported proteolytic MALT1 substrates [9,10].
Rebeaud et al. [10] found MALT1 to cleave its binding partner
Bcl10, whereas Coornaert et al. [9] reported cleavage of the
negative NF-κB regulator A20. To date, three further substrates,
NIK(NF-κB-inducingkinase),CYLDandRelB,havebeenfound
[11–13]. The results of substrate cleavage are diverse and include
activation of canonical and non-canonical NF-κBa sw e l la sJ N K
(c-Jun N-terminal kinase) signalling [9,11–13] and increased T-
cell-receptor-controlled binding to ﬁbronectin [10].
All reported MALT1 substrates are cleaved directly C-
terminal to an arginine residue in the P1 position (according
to Schechter and Berger [14] nomenclature, P1 corresponds
to the amino acid directly N-terminal to the cleavage site).
Thus MALT1 has been proposed to be an arginine-speciﬁc
protease. To test this proposal, and to deﬁne the substrate
preference, catalytic properties and activation mechanism of
MALT1,wehaveperformedbiochemicalcharacterizationstudies
of puriﬁed recombinant MALT1 expressed in Escherichia
coli.
EXPERIMENTAL
Materials
All chemicals were purchased from commercial suppliers unless
otherwise stated. See individual sections for details.
Protein expression and puriﬁcation
Constructs encoding full-length MALT1-WT (wild-type) and
-C464A were a gift from Dr Margot Thome (Department of
Biochemistry, University of Lausanne, Lausanne, Switzerland).
These were cloned into a modiﬁed pET29b vector (Novagen)
Abbreviations used: Ac, acetyl; ACC, 7-amino-4-carbamoylmethylcoumarin; AFC, 7-amino-4-triﬂuoromethylcoumarin; AMC, 7-amino-4-methylcoumarin;
BIR, baculovirus inhibitor of apoptosis protein repeat; CARD, caspase recruitment domain; CARMA1, CARD-containing MAGUK (membrane-associated
guanylate kinase) 1; cIAP2, cellular inhibitor of apoptosis protein 2; DD, death domain; DTT, dithiothreitol; FKBP, FK506-binding protein; FMK,
ﬂuoromethylketone; HEK, human embryonic kidney; IAP, inhibitor of apoptosis protein; IPTG, isopropyl β-D-thiogalactopyranoside; JNK, c-Jun N-terminal
kinase; MALT1, mucosa-associated lymphoid tissue lymphoma translocation protein 1; NF-κB, nuclear factor κB; NIK, NF-κB-inducing kinase; Ni-NTA,
Ni2+-nitrilotriacetate; PS-SCL, positional-scanning substrate combinatorial library; TCA, trichloroacetic acid; WT, wild-type; z, benzyloxycarbonyl.
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Figure 1 Domain structure and puriﬁcation of MALT1
(A)DomainstructureofMALT1.(BandC)His-taggedfull-lengthMALT1(B)andthecatalyticdomain(aminoacids329–566)(C)wereexpressedinE.coli andpuriﬁedusingaNi-NTAcolumn.Lane
1, molecular mass markers; lane 2, total cell lysate; lane 3, soluble material after sonication; lane 4, the eluted protein fraction with full-length (FL) MALT1 (B) and catalytic domain (C) respectively,
depicted by arrows. The band marked with an asterisk (*) was N-terminally sequenced and found to be the E. coli heat-shock protein DnaK. (D) Full-length and catalytic domain MALT1 were titrated
with the depicted concentration range of the irreversible inhibitor z-VRPR-FMK. The linear portion of the titration curve was extrapolated to its int e r c e p to ft h ex-axis to reveal the active concentration
of the respective MALT1 preparations.
containing an N-terminal Strep II tag and a C-terminal His
tag and transformed into BL21(DE3) E. coli cells. Protein
expression was induced with 0.04 mM IPTG (isopropyl β-D-
thiogalactopyranoside) and cultures were grown overnight at
18◦C. The soluble fraction was applied to a Ni-NTA (Ni
2+-
nitrilotriacetate) column and eluted with 200 mM imidazole or,
for increased purity, an imidazole gradient from 0 to 200 mM in
50 mM Hepes and 100 mM NaCl (pH 7.5). The catalytic domain
(amino acids 329–566) [8] was cloned into pET21b (Novagen)
containing a C-terminal His tag. It was expressed and puriﬁed
as above except that 0.2 mM IPTG was used and cultures were
grown at 25◦C for 4 h. The protein concentration was determined
by absorbance at 280 nm on the basis of the estimated molar
absorptioncoefﬁcient[15].ProteinswereresolvedbySDS/PAGE
(8% or 8–18% gels) and stained with Gel Code Blue reagent
(Thermo Scientiﬁc).
Synthesis and assay of the P2–P4 PS-SCL (positional-scanning
substrate combinatorial library)
The ACC (7-amino-4-carbamoylmethylcoumarin)-coupled PS-
SCL was synthesized on the basis of a concept described
previously [16]. Arginine was ﬁxed in the P1 position. After
synthesis, each sub-library was dissolved at a concentration
of 2.5 mM in biochemical-grade dried DMSO and stored at
−20◦C until use. Each sub-library contained 361 individual
substrates and was measured at a total substrate concentration of
50 μM (individual substrates at a concentration of approximately
138.5 nM).Full-lengthandcatalyticdomainMALT1(seeFigures
for enzyme concentrations) were pre-incubated at 37◦C in assay
buffer [50 mM Hepes, 100 mM NaCl, 0.9 M sodium citrate and
10 mM DTT (dithiothreitol) (pH 7.5)] plus (for the catalytic
domain)1 mMEDTAfor20 minbeforeadditiontothelibraryand
measurementofsubstratehydrolysisrates.Releaseofﬂuorophore
was monitored continuously with excitation at 355 nm and
emission at 460 nm with an assay time of 2 h. Rates were
determined from the linear portion of the progress curves. The
maximum value of each sub-library was set at 100% and the
other values were adjusted accordingly.
Synthesis and assay of the P1 library
All substrates for the screening of the P1 position with the
sequence Ac-Leu-Arg-Ser-X-ACC, where Ac is acetyl and X
represents either a natural amino acid or norleucine as a substitute
for methionine, as well as other individual ﬂuorigenic ACC-
coupled substrates, were synthesized on a solid-state support
(Rink resin) and puriﬁed using reverse-phase HPLC preparatory
chromatography according to a protocol described previously
[17]. Substrates were tested at a concentration of 10 μM in assay
bufferplus1 mMEDTA.Beforeadditionofthesubstrate,enzyme
was pre-incubated in buffer for 20 min at 37◦C. Catalytic rates
were determined as described in the previous section.
Comparison of substrates
Cleavage of ﬂuorigenic substrates of different lengths by full-
l e n g t ho rc a t a l y t i cd o m a i nM A L T 1w a st e s t e di na s s a yb u f f e rp l u s
1 mM EDTA. Enzyme was pre-incubated in buffer for 20 min
at 37◦C before addition of the substrate at a concentration of
approximately 20 μM. To determine catalytic rates, different
potentialMALT1substrateswereassayedbetween0and100 μM
in assay buffer plus 1 mM EDTA. Before addition of substrate,
MALT1 was pre-incubated at 37◦C in buffer as described above.
AFC (7-amino-4-triﬂuoromethylcoumarin)- and AMC (7-amino-
4-methylcoumarin)-coupled peptide substrates were obtained
from SM Biochemicals. The active concentration of enzyme for
the determination of catalytic rates was determined by titration
withtheirreversibleinhibitorz-VRPR-FMK(EnzoLifeSciences)
(where z is benzyloxycarbonyl, VRPR is Val-Arg-Pro-Arg and
FMK is ﬂuoromethylketone) [18].
Hofmeister series
MALT1 (full-length and catalytic domain) was assayed in 50 mM
Hepes, 10 mM DTT and 1 mM EDTA (pH 7.5), with salt
concentrations rangingfrom 0to 1 M. Enzymewas pre-incubated
for 20 min at 37◦C in the appropriate buffers before addition
of Ac-LRSR-AFC at 100 μM and determination of the initial
velocity.
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Concentration-dependence of activity
Full-length MALT1 at a constant concentration of 500 nM was
assayed in 50 mM Hepes, 100 mM NaCl, 10 mM DTT and 1 mM
EDTA (pH 7.5) with citrate concentrations varying between 0.1
and0.9 M.Thereactionsweresupplementedwithcatalyticmutant
at the concentrations indicated in Figure 1(D) and pre-incubated
for 20 min at 37◦C before the addition of 100 μMA c - L R S R -
AFC.
Expression and puriﬁcation of CYLD
A construct encoding recombinant human CYLD (isoform 2)
was a gift from Dr Sumit Chanda (Sanford-Burnham Medical
Research Institute, La Jolla, CA, U.S.A.). It was cloned with a
C-terminalFLAGtaginpCDNA3.1(Invitrogen)andexpressedin
and puriﬁed from HEK (human embyonic kidney)-293T cells as
follows. Cells were grown to ∼60% conﬂuence in 10 cm tissue
culture dishes and transfected with 5 μg of plasmid DNA/dish
using Nanojuice (Novagen/EMD Chemicals), according to the
manufacturer’s instructions. After transfection, cells were grown
overnight, harvested, pooled, washed with PBS and lysed in 1 ml
of cell lysis buffer [50 mM Hepes, 150 mM KCl, 0.1% CHAPS
and 1% Nonidet P40 (pH 7.4)] supplemented with protease
inhibitors [E-64, MG132, 3,4-DCI (3,4-dichloroisocoumarin),
pepstatin, PMSF and aprotinin (all at 10 μM) and 100 μM
EDTA] for 20 min on ice. The cleared lysate was collected after
centrifugation and incubated overnight with 20 μlo fw a s h e dM 2
anti-FLAGbeads.Proteinwaselutedfromthebeadsafterwashing
away the unbound material with 40 μlo f3 ×FLAG peptide at a
concentration of 5 mg/ml in PBS for 20 min on ice.
Stability of MALT1 in sodium citrate buffer
Full-length MALT1-WT and -C464A were incubated at 1.5 μM
in assay buffer plus 1 mM EDTA for various time periods
followed by TCA (trichloroacetic acid) precipitation. Samples
were resolved by SDS/PAGE (8–18% gels) and stained with
Gel Code Blue reagent. For N-terminal sequencing, proteins
were resolved by SDS/PAGE, followed by Western blotting on
to PVDF membrane. The membrane was stained with Coomassie
BrilliantBlue,andtheappropriatebandsweresubjectedtoEdman
degradation using an ABI Procise 492.
In vitro cleavage of protein substrates
CYLD-WT was diluted to a 1 μM ﬁnal concentration and
incubated with various concentrations of active full-length
MALT1 or  DED-caspase 8 (puriﬁed as described previously
[18])respectivelyfor1 hat37◦Cin20mMPipes,100mMNaCl,
0.8 M sodium citrate and 10 mM DTT (pH 7.2). The reaction
was stopped by TCA precipitation. Cleavage was subsequently
assessed by SDS/PAGE (8–18% gels), followed by Western
blotting with an anti-CYLD antibody [rabbit anti-CYLD, pAb
(polyclonal antibody) AF888 from Enzo Life Sciences] or with
an anti-FLAG antibody (clone M2, Sigma–Aldrich). Blots were
scanned on an Odyssey infrared scanner (LI-COR Biosciences)
and the ﬂuorescent signal of full-length protein and the cleaved
productwasusedtodetermineE1/2,representingtheconcentration
of protease that cleaves 50% of the full-length substrate in time
(t). The apparent value for kcat/Km was then determined with the
half-life equation [18]:
kcat
Km
=
ln2
tE1
2
RESULTS
Expression and puriﬁcation of MALT1
To characterize the substrate speciﬁcity and the catalytic
properties of MALT1, we expressed His-tagged versions of both
the catalytic domain alone (amino acids 329–566) and the full-
length protein in E. coli (Figures 1B and 1C). On the basis
of the protein concentration estimated from the absorbance at
280 nm,active-sitetitrationwiththeirreversibleMALT1inhibitor
z-VRPR-FMK [10] revealed that the preparations of the catalytic
domain alone contained only an estimated 5–10% of active
protein depending on the protein preparation, whereas the full-
length protein was found to be fully active (Figure 1D). The
reason for this could not be determined, but may be due to
partly aggregated or denatured protein, implying that the catalytic
domain alone is not as stable as the full-length protein. Mutation
of the putative catalytic Cys
464 to alanine (full-length numbering)
abrogated catalytic activity for both versions on all of the
substrates tested (results not shown).
In vitro activation of MALT1 by sodium citrate
In regular low-salt buffers or buffers with ionic concentrations
in the physiological range, neither full-length nor catalytic
domain MALT1 showed any proteolytic activity in our hands.
Kosmotropic salts have been shown to increase the activity of
many enzymes [19–22], the extent of which depends on the
active state of the enzyme in question. To explore this aspect, we
determined the ability of a number of different salts to generate
activity in full-length and catalytic domain MALT1 (Figures 2A
and 2B). High concentrations of sodium citrate or sodium sulfate
dramatically enhanced the catalytic activity of both full-length
and catalytic domain MALT1, more than 1000-fold, and lithium
sulfate showed a minor activation. In contrast, NaCl and LiCl
showed no activating potential. These results are fully consistent
withtheHofmeistereffect.Itisnotentirelyclearhowkosmotropic
salts of the Hofmeister series activate enzymes, but it is believed
that they decrease the entropy in the system, thereby allowing
ordering and oligomerization processes to take place that are
normally entropically unfavourable [23]. On the basis of these
results,sodiumcitratewasdeterminedastheactivatorofchoice.In
linewiththepredictionthatMALT1isacysteineprotease,activity
wasenhancedbyDTT,whichprobablyservestoreverseoxidation
of the catalytic cysteine residue that occurs during puriﬁcation.
CaCl2, EDTA and 1,10-phenanthroline had no substantial effect
on the activity of MALT1, demonstrating that it is probably not a
metal-dependent enzyme (Figure 2C and results not shown).
Activation mechanism
Kosmotrope-mediated ordering of active-site loops can increase
the activity of a protease severalfold. In addition, enzymes that
are activated by oligomerization can show much higher increases
in activity [20]. MALT1 showed no activity in the absence of
kosmotropes and a robust increase in the presence of sodium
citrate, and we postulated that this represents activation by
oligomerization.
To elucidate this further, we studied the effect of the protein
concentration on the activation of MALT1, hypothesizing that
an oligomerization process would decrease the requirement for
sodium citrate activation. We assayed a constant concentration
of MALT1-WT in buffers with increasing sodium citrate
concentrations (Figure 2D). We then added increasing amounts
of MALT1-C464A to this constant amount of MALT1-WT to
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Figure 2 MALT1 activation
(A–C) Different salts and buffer additives were screened for MALT1-activating potential. Full-length (150nM) and catalytic domain (4 μM) MALT1 were assayed in 50mM Hepes (pH7.5), 10mM
DTT and 1mM EDTA,supplementedasdepicted (A and B) or in 50mM Hepes,100mMNaCland 0.9 M sodiumcitrate (pH7.5) supplementedasdepicted (C).(D) Full-length MALT1-WT (500nM)
was assayed in buffers with various citrate concentrations and supplemented with full-length catalytic mutant as depicted. The experiments were repeated three (A–C)o rt w o( D) times respectively.
Mean values and S.E.M. are shown.
determine whether high concentrations of MALT1 decrease the
inﬂuence of citrate on MALT1 activity. We found that at high
sodium citrate concentrations, increasing the amount of enzyme
only had a mildly activating effect. However, at low sodium
citrateconcentrations,increasingtheamountofenzymebyadding
MALT1-C464A led to a linear increase in MALT1 activity. We
thereforespeculatethatMALT1existsasamixtureofmonomeric
and oligomeric species. Sodium citrate addition and increased
protein concentrations both shift this equilibrium towards the oli-
gomeric (active) state. An unrelated control protein (catalytically
inactive SENP1) had no effect on MALT1 (results not shown).
However, it is important to note that even the addition of very
high concentrations of catalytic mutant to MALT1-WT at low
citrate concentrations did not yield nearly as much activity as
MALT1-WT at high citrate concentrations, either with or without
the catalytic mutant. We conclude from this that sodium citrate
acts in multiple ways, driving both the oligomerization processes
and overall protein stabilization. The more the equilibrium
favours oligomerization, as a consequence of a high enzyme
concentration, the smaller the requirement for citrate becomes.
We sought to investigate the active conformation of MALT1
further by size-exclusion chromatography experiments of
activated MALT1, but were unsuccessful because the activity of
MALT1wasfoundnottobestableuponcitratedepletionandhigh
salt concentrations compromised the chromatography (results not
shown).
MALT1 is active in the full-length unprocessed form
To further determine the mechanism of activation and the
active conformation of MALT1, we tested whether the ob-
served activation through sodium citrate leads to autoprocessing
of MALT1. As visualized via SDS/PAGE in Figure 3, MALT1
remains largely unprocessed even after 2 h in sodium citrate,
which leads to its activation. Several bands are visible in addition
tofull-lengthMALT1,butallareseenbothintheWTandcatalytic
mutant, which rules out that they are autoprocessing products of
Figure 3 Sodium citrate does not activate MALT1 via cleavage
Full-length MALT1-WT and -C464A (C/A) were activated in assay buffer plus EDTA for the
indicated times at 37◦C. Reactions were stopped by TCA precipitation and samples were
resolved by SDS/PAGE. The identity of all bands was determined via N-terminal sequencing.
His-rich, FKBP-type peptidylprolyl cis–trans isomerase slyD (histidine-rich binding protein).
The asterisk marks a protein that could not be clearly identiﬁed due to its low intensity, but
partialsequencingshowedthatitdid notmatchthesequenceofMALT1.Themolecularmassin
kDa is indicated on the left-hand side.
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Figure 4 MALT1 substrate speciﬁcity
(A) MALT1 speciﬁcity was determined using a tetrapeptide P1 library consisting of Ac-LRSX-ACC (P1) and a P1-Arg PS-SCL (P2, P3 and P4). Full-length (130nM) and catalytic domain MALT1
(5 μM)wereanalysed inassaybuffer.Hydrolysisratesweredeterminedandpresentedasafraction ofthemaximalratein eachsubsetlibraryposition.The x-axesrepresenttheaminoacidsdepicted
using the one-letter code (O, norleucine). (B and C) Cleavage of ﬂuorigenic peptides of various lengths by full-length (B, 80nM) or catalytic domain (C,4μM) was determined in assay buffer plus
EDTA. The highest activity in each assay was set as 100%; all other activities are shown relative to this. All assays were repeated at least three times. Mean values and S.E.M. are shown.
MALT1.WeinvestigatedtheiridentityviaN-terminalsequencing
and found them to be E. coli impurities, rather than MALT1
autocleavageproducts.WethereforeconcludethatMALT1isact-
iveinitsfull-lengthunprocessedforminvitroanddoesnotprocess
itself upon sodium citrate treatment in signiﬁcant amounts.
Substrate speciﬁcity
Speciﬁcity of proteases is conventionally determined using
ﬂuorigenic or chromogenic reporter-coupled peptides as
substrates that occupy the catalytic cleft of the enzyme. Thus,
to determine the inherent substrate speciﬁcity of both full-
length MALT1 and the catalytic domain, we screened a PS-SCL
consisting of ﬂuorigenic tetrapeptides.
MALT1 is commonly referred to as an arginine-speciﬁc
protease. To further determine its substrate speciﬁcity, MALT1
was tested on a peptide library with the P1 position ﬁxed to
arginine and the P2, P3 and P4 positions varied to represent all
possiblecombinationsofproteinogenicaminoacids(cysteinewas
omitted and norleucine was substituted for methionine). The full-
length and the catalytic domain showed comparable substrate
speciﬁcity (Figure 4A). The P2 position was moderately selective
for amino acidswith small side chains,with thesmall polarserine
residue as well as non-polar hydrophobic amino acids such as
proline and alanine residues well tolerated. MALT1 exhibited the
greatest tolerance in the P3 position. The preferred amino acid in
this position was valine, but it was closely followed by other non-
polar hydrophobic amino acids and even polar charged residues
werereasonablywelltolerated.However,withinthislibraryitwas
the P4 position that showed the highest level of selectivity, with
leucine clearly favoured. The closely related norleucine residue
as well as isoleucuine were also tolerated, whereas polar residues
in the P4 position completely abrogated protease activity.
After determining the P2, P3 and P4 speciﬁcities, we went on
to test the selectivity for arginine in the P1 position using a P1
library. To decrease the number of non-cleavable substrates in the
mixture and therefore increase the sensitivity of the approach,
theP2,P3andP4positionswereﬁxedtoresiduesfoundfavourable
in the previous library screen. However, the optimal sequence
LVSX contains two hydrophobic residues. In combination with
an additional hydrophobic amino acid in the P1 position this
can lead to solubility issues. We therefore synthesized a P1
library consisting of the less hydrophobic, yet still well tolerated,
sequence Ac-LRSX-ACC (X representing all amino acids except
cysteine; norleucine was substituted for methionine). Using this
approach, high selectivity for arginine in the P1 position could be
conﬁrmed (Figure 4A, right-hand panels). Additionally, a minor
yet consistent activity on tyrosine and to a lesser extent histidine
in P1 was observed.
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Table 1 Catalytic efﬁciencies of MALT1
Comparative catalytic efﬁciencies of full-length and catalytic domain MALT1. Values for the enzyme concentration were obtained using active-site-titrated enzymes, as described in the Experimental
section. Standard errors are derived from non-linear regression analysis of the general Michaelis–Menten equation compared with the experimental data points. ALVSR, Ala-Leu-Val-Ser-Arg; LRSR,
Leu-Arg-Ser-Arg; LVSR, Leu-Val-Ser-Arg.
Substrate [Enzyme] (nM) kcat (s−1) Km (μM) kcat/Km (M−1 ·s−1)
Full-length-MALT1
Ac-LVSR-ACC 399 0.071 (+ −0.0018) 15.3 (+ −1.1) 4.6×103
Ac-ALVSR-ACC 399 0.059 (+ −0.0025) 7.1 (+ −0.9) 8.4×103
Ac-LRSR-ACC 399 0.021 (+ −0.0014) 15.6 (+ −2.4) 1.3×103
Ac-LRSR-AMC 399 0.049 (+ −0.0024) 34.5 (+ −3.9) 1.4×103
Ac-LRSR-AFC 399 0.092 (+ −0.0036) 37.4 (+ −3.2) 2.5×103
Catalytic domain
Ac-LVSR-ACC 285 0.095 (+ −0.0043) 8.9 (+ −1.3) 1.1×104
Ac-ALVSR-ACC 285 0.093 (+ −0.0036) 3.0 (+ −0.4) 3.1×104
Ac-LRSR-ACC 285 0.044 (+ −0.0011) 12.6 (+ −0.8) 3.5×103
Ac-LRSR-AMC 294 0.057 (+ −0.0033) 19.5 (+ −3.1) 2.9×103
Ac-LRSR-AFC 294 0.070 (+ −0.0036) 15.3 (+ −2.2) 4.6×103
It is important to note that the presence of EDTA did not
inﬂuence the substrate speciﬁcity of MALT1. The PS-SCL was
tested both in the absence and presence of EDTA and no
substantial differences were observed. To underline this, the
results are shown in the absence of EDTA for the full-length and
inthepresenceofEDTAforthecatalyticdomain(Figure4A).The
optimal P4–P1 substrate preference of MALT1 was determined
to be Leu-Val-Ser-Arg.
MALT1 has a minimum substrate length requirement for substrate
hydrolysis
After determining the substrate speciﬁcity, peptides of various
lengths were synthesized to verify both the PS-SCL results and
determine the signiﬁcance of the sequence length. Interestingly, a
lengthofatleastfourresidueswasabsolutelyrequired(Figures4B
and 4C). No cleavage was observed if shorter peptides were used,
even at a substrate concentration up to 20 μM. A pentapeptide
composed of the four optimal residues determined in the library
and alanine as an additional amino acid in the P5 position was
designed. This elongation slightly increased the ability of the
protease to cleave efﬁciently, but no stark increase, as for
the switch from tripeptide to tetrapeptide, was observed.
The direct comparison of MALT1 activity on the Leu-Arg-Ser-
Argpeptide,asoftenusedintheliteratureaswellasthroughoutthe
present study, with the Leu-Val-Ser-Arg peptide found as optimal
in the library screen, showed the latter to have a 3–4-fold higher
kcat/Km (Table 1), conﬁrming data published by Hailﬁnger et al.
[11]. This rather small difference again underlines the relatively
ﬂexible substrate preference of MALT1 in the P3 position.
Increasingthesubstratelengthfromtetra-topenta-peptidefurther
increased the catalytic efﬁciency 2–3-fold (Table 1). Owing to the
inherent design of the PS-SCL, it was not possible to screen
for preferences in P
  positions (C-terminal to the scissile bond).
To determine whether changes in the ﬂuorophore could alter the
cleavage efﬁciency, Ac-Leu-Arg-Ser-Arg coupled to AMC, AFC
and ACC was assayed. ACC contains a bulkier side chain than
AMC and AFC, but no substantial differences were seen between
the kcat/Km ratios of these three substrates (Table 1).
Cleavage of protein substrates
MALT1 and caspase 8 were both recently reported to cleave
the deubiquitinating enzyme CYLD. MALT1 cleaves after Arg
324
(isoform 1 numbering), activating JNK signalling [13], whereas
caspase 8 was reported to cleave after Asp
215, abrogating
necroptosis [24]. To compare catalytic efﬁciencies, we puriﬁed
recombinant CYLD from HEK-293 cells and incubated it with
increasing amounts of recombinant full-length MALT1 or the
catalyticdomainofcaspase8underidenticalconditions,followed
by analysis by SDS/PAGE (Figure 5). We found CYLD to be
cleaved slightly more efﬁciently by MALT1 (kcat/Km,1 . 4 ×10
3
M
−1 ·s
−1)t h a nb yc a s p a s e8( kcat/Km,1 . 2 ×10
3 M
−1 ·s
−1).
DISCUSSION
Activation mechanism
MALT1 has been reported to be activated in vivo downstream
of several immune activation receptors in a protein assembly
known as the CBM complex [3–6]. Mechanistically, there are
three distinct ways that a protease such as MALT1 can become
active: proteolytic cleavage, conformational rearrangement of
a monomer or conformational changes brought about by
dimerization. We demonstrate that cleavage of MALT1 is not
necessary for its activation. During the preparation of this paper,
the crystal structure of the catalytic domain of MALT1, together
with the C-terminally adjoining Ig-like domain, was published,
revealingadimericarrangementmediatedbythecatalyticdomain
[25]. Our exploration of the activation mechanism using puriﬁed
full-lengthandcatalyticdomainMALT1addsdirectexperimental
support to the idea that activation of proteolytic activity occurs
through dimerization.
As well as the now identiﬁed structure of MALT1 itself, it is
interestingtocomparestructuresofMALT1homologuesandtheir
mechanisms of activation for further insight into the mechanism
of activation. MALT1 is a member of the peptidase clan CD,
which includes caspases and caspase homologues [26]. Members
of the caspase family can be activated via two main routes, but
all caspases are active as dimers. The apical caspases 8, 9 and
10 are activated through dimerization, followed by a stabilizing,
yet dispensable, cleavage reaction [20]. On the other hand, the
executioner caspases 3 and 7 are obligate dimers that require
cleavage for activation [27,28].
Another clan CD member worth considering is the arginine-
speciﬁc protease R-gingipain. The crystal structure showed that
in its active conformation the caspase-like domain of R-gingipain
issubdividedintoacatalyticdomainandastabilizingcapdomain.
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Figure 5 Cleavage of CYLD by MALT1 and caspase 8
(A and B) FLAG-tagged human CYLD was puriﬁed from HEK-293 cells and incubated with 2-fold increasing concentrations of full-length MALT1-WT (A) or caspase 8-WT (B) respectively. Samples
were resolved by SDS/PAGE, followed by Western blotting and detection with an antibody against the N-terminal domain of CYLD (top panels) and anti-FLAG antibody (bottom panels) respectively.
Data are representative of three independent experiments. (C) Linear regression used to determine the kcat/Km values. Mean values and S.D. are shown. (D and E) Different FLAG-tagged CYLD
mutants were puriﬁed as in (A) and incubated with the WT or catalytic mutant versions of full-length MALT1 (D) or caspase 8 (E) respectively at 1μM. (F) Overview of CYLD domains and cleavage
sites. CAP-Gly, cytoskeleton-associated protein glycine-rich domain; DUB, deubiquitinating enzyme domain.
Both domains interact with an Ig-like domain, which further
stabilizes the protein [29,30]. This is an interesting similarity
to the structure of the catalytic domain of MALT1, which was
crystallized together with an adjacent Ig-like domain. However,
theIg-likedomainsofR-gingipainandMALT1interactwiththeir
respectiveproteasedomains,atleastinthecrystalstructures,using
different surfaces. In contrast with MALT1 and the caspases, R-
gingipain, after several processing steps, is active as a monomer
and does not require kosmotropic salts for activation. Thus
MALT1 resembles apical caspases in its activation through
dimerization.
The domain structure of MALT1 reveals an N-terminal DD,
followed by two Ig-like domains, a caspase-like domain and
another Ig-like domain (Figure 1A). Next to the catalytic domain,
the crystal structures of the DD, as well as two Ig-like domains,
were recently published [31]. The N-terminal Ig-like domains
of MALT1 (amino acids 129–326) were found to behave as
a tetrameric species involving a total of eight Ig-like domains,
conceivably mimicking a multimeric activation platform. Other
studies also support a multimeric platform for MALT1 activation.
The oncogenic fusion protein where the DD (and sometimes
the N-terminal Ig-like domains) of MALT1 are replaced by the
three BIR (baculovirus IAP repeat) domains of cIAP2 was
shown to constitutively activate the NF-κB pathway and promote
cleavage of target proteins [2,9,12,13]. This is proposed to
occur though dimerization, which could be mediated either
through homotypic interactions between the BIR1 domains [32]
or heterotypic interactions involving both the BIR domains and
the C-terminal portion of MALT1 [33]. MALT1 dimerization
hybrids with a gyrase B or helix–loop–helix domain, as well as
multiple FKBP (FK506-binding protein) domains were shown
to exhibit activity and NF-κB activation in cell transfection
experiments [6,9,34]. Thus activation by dimerization resembles
the mode of apical caspases, whose respective oligomerization
assembliesprovideplatformsforthetransitionoflatentmonomers
toactivedimers[35].Importantly,althoughtheaccessorydomains
of MALT1 are probably required for activation in vivo, our
experiments demonstrate that the caspase-homology protease
domain alone (devoid of Ig-like domains) is fully capable of
providing maximal catalytic activity in vitro. We have not yet
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been able to determine the dimerization equilibrium constant
for MALT1, but it would seem to have a similar barrier for
dimerization as the apical caspases, because MALT1 requires
similar kosmotrope concentrations for optimal activation as
caspases 8 and 10 [19].
Substrate speciﬁcity
Using PS-SCL we were able to determine the optimal cleavage
sequence for MALT1. Both full-length and catalytic domain
MALT1 prefer the P4–P1 sequence Leu-Val-Ser-Arg↓, with
arginine being a near absolute requirement in the P1 position and
leucine being strongly favoured in P4. The sequence determined
matches the cleavage site in the reported natural substrate RelB
perfectly [11]. The cleavage site of Bcl10 (Leu-Arg-Ser-Arg↓)
is also very well matched [10]. However, looking at the other
reported natural substrates, the fairly strict requirement for a
leucine residue in P4 might seem surprising. Of the ﬁve protein
substrates reported so far, only two show leucine in this position,
whereas CYLD is cleaved after Phe-Met-Ser-Arg↓, NIK after
Cys-Leu-Ser-Arg↓and,remarkably,A20afterGly-Ala-Ser-Arg↓
(aglycineresidueinP4),which,accordingtothelibraryscreening
results, is poorly tolerated. Notably, A20 contains leucine in
the P5 position, which is favoured for cleavage by MALT1 (J.
Staal, personal communication). Interestingly, MALT1 contains
a large hydrophobic patch that forms the S4 pocket [25] that
could, in principle, also accommodate a hydrophobic P5 residue
to overcome the penalty of glycine in P4. In accordance with
the broad P2 and P3 preferences obtained from our library
data, the crystal structure demonstrates that these residues form
fewer contacts with the S2 and S3 pockets [25], although the
crystal structure would not appear to explain the preference for
small side chains at P2.
The fairly strict preference in the P4 position is interesting
considering that MALT1 is a caspase homologue. In caspases, the
P4 position often plays a dominant role in promoting substrate
speciﬁcity differences between paralogues [36]. Importantly, a
length of at least four amino acids is required for cleavage to
occur, another similarity to the caspases, which require substrates
elongated beyond tripeptides for efﬁcient cleavage [37].
Optimal peptide substrates were cleaved with rates (kcat/Km)o f
up to 10
4 M
−1 ·s
−1, which is two to three orders of magnitude
lowerthanforoptimalcaspaseorgingipainsubstrates[30,38].The
low catalytic rates combined with the rather strict requirement for
leucine in P4 explain why initial library screens conducted in our
group several years ago did not reveal any proteolytic activity [8].
Thus MALT1 has a generally lower catalytic activity than other
members of the clan to which it belongs, or additional factors
are required to enhance activity of the recombinant material. It is
important to keep in mind that, for the cleavage of natural protein
substrates as opposed to peptide substrates, exosite interactions
betweenproteaseandsubstrateoftenenhancecleavageofproteins
that have non-optimal residues occupying the catalytic cleft [39].
From this perspective it is illuminating to consider the rate of
cleavage of the natural substrate CYLD. kcat/Km was estimated at
1.4×10
3 M
−1 ·s
−1,renderingthisaslightlylessefﬁcientcleavage
than the optimal peptide substrates. This raises the question as
to whether MALT1 is simply not a very efﬁcient protease on its
naturalsubstratesorpeptidereportersubstratesinvitro,orwhether
its truly optimal natural substrate has not yet been discovered.
Even though some of the substrates determined to date show
cleavage site sequences that are remarkably close to or identical
with the sequence determined as optimal during the screening
of the PS-SCL, it is important to keep in mind that MALT1
may enhance catalysis in vivo by an exosite-driven mechanism
translating it from an enzyme of average efﬁciency to a highly
effective protease given its ideal substrate.
Finally, we are struck by the similar rates of processing of
CYLD by both MALT1 and caspase 8, representing a survival
function for this apical caspase [24]. Since both of these events
are reported to occur downstream of T-cell-receptor signalling
[13,24] one would expect the distinct cleavages (see Figure 5F) to
occur simultaneously since they have similar cleavage kinetics.
If this is the case, the consequences of the MALT1 cleavage,
leading to JNK activation [13], would be dominant since the fate
of caspase 8-cleaved CYLD is degradation [24]. Naturally, the
kinetics will depend on the rate of activation of the two proteases,
and the rate of encounter within subcellular activation complexes.
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